Empowering Innovation: Accelerating Translation
We bring together the sector to help innovators with early-stage antimicrobial and diagnostic projects move forward with greater speed and confidence, accelerating the delivery of new innovations to tackle AMR.
PACE aims to offer a collaborative approach to project development and delivery. We will support PACE awardees to align their AMR asset with the right translational roadmap and ensure supporting data packages are appropriately targeted and strengthened. PACE awardees will also benefit from a network of potential delivery partners, advisors and mentors to help them develop their AMR assets at pace.
- Microbial diagnostics
- Antimicrobial compound/strategy
- Infection prevention
- Antimicrobial stewardship
- Removal antibiotics/bacteria
- Market entry
- Marketed product
- Joint Venture
- OTHER / NA
Infectious disease area:
- North America
- South America
We are looking for innovators, delivery partners and strategic partners to help us create and support a new early pipeline
PACE (Pathways to Antimicrobial Clinical Efficacy) is a £30 million initiative supporting early-stage innovation in medicines and diagnostics to tackle AMR. It is a collaboration between Innovate UK, LifeArc, and Medicines Discovery Catapult and aims to work with the global AMR community to accelerate the speed of innovation to mitigate the risk of AMR.
PACE is looking to connect with the community to identify and support portfolio projects with the most transformative potential in tackling AMR.